Product Description
Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002656/)
Mechanisms of Action: BLyS Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: Breakthrough Therapy - IgA Nephropathy *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vera Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Marshall Fordyce
Additonal Commercial Interests: Merck
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hong Kong, India, Ireland, Italy, Malaysia, Philippines, Poland, Portugal, Puerto Rico, Singapore, South Korea, Spain, Sri Lanka, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Glomerulonephritis|IgA Nephropathy|Kidney Diseases|Lupus Nephritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031230629 | P3 |
Recruiting |
IgA Nephropathy |
2029-04-12 |
|
| VT-001-0050 | P3 |
Unknown Status |
IgA Nephropathy |
2028-11-24 |
|
| ORIGIN EXTEND | P2 |
Not yet recruiting |
Kidney Diseases|IgA Nephropathy|Glomerulonephritis |
2028-05-31 |
|
| COMPASS | P3 |
Active, not recruiting |
Lupus Nephritis |
2026-11-21 |